期刊
JOURNAL OF MEDICAL GENETICS
卷 48, 期 8, 页码 523-525出版社
B M J PUBLISHING GROUP
DOI: 10.1136/jmg.2010.087379
关键词
-
资金
- Susan G Komen Foundation for the Cure
- Jewish General Hospital
- Breast Cancer Research Foundation
- Taub Family Research Initiative
- Robert and Kate Niehaus Clinical Cancer Genetics Initiative
- Lymphoma Foundation
- Fonds de la Recherche en Sante du Quebec (FRSQ)
Background Germline mutations in the PALB2 gene have been implicated in both breast cancer and pancreatic cancer susceptibility. The extent to which PALB2 mutations account for cancer susceptibility in breast-pancreas cancer families is unknown. Methods High Resolution Melting analysis and Multiplex Ligation-dependent Probe Amplification were performed to investigate the prevalence of PALB2 mutations in patients with either a personal history of both breast and pancreatic cancer or a personal history of breast cancer and a family history of a first degree relative with pancreatic cancer. Results No PALB2 mutations were identified in 77 breast-pancreas cancer families, which included 22 probands with a personal history of both breast and pancreatic cancer. Conclusion Mutations within the PALB2 gene are rare events that do not account for a substantial proportion of cancer susceptibility in breast-pancreas cancer families. Routine screening of breast-pancreas cancer families for the presence of PALB2 mutations appears to be low yield.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据